Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Sep 2, 2015
Sangamo and Shire Restructure Collaboration to Accelerate Development of ZFP Therapeutics® for the Treatment of Hemophilia and Huntington's Disease

Aug 5, 2015
Sangamo BioSciences Reports Second Quarter 2015 Financial Results


View all »Events & Presentations

Sep 2, 2015 at 5:00 AM PT
Sangamo Teleconference Call

Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
7.15
Change:
- 0.50
Day High:
7.71
Day Low:
6.85
Volume:
2,369,200
4:00 PM ET on Sep 2, 2015

Shareholder Tools